Use your antibodies-online credentials, if available.
Human Polyclonal DLC1 Primary Antibody for IHC (p), IHC - ABIN268701
Ko, Yeung, Wong, Chan, Poon, Ng, Yam: Deleted in liver cancer 1 isoforms are distinctly expressed in human tissues, functionally different and under differential transcriptional regulation in hepatocellular carcinoma. in Liver international : official journal of the International Association for the Study of the Liver 2009
Show all 2 Pubmed References
Human Polyclonal DLC1 Primary Antibody for IHC, IHC (p) - ABIN4305321
Muehlich, Hampl, Khalid, Singer, Frank, Breuhahn, Gudermann, Prywes: The transcriptional coactivators megakaryoblastic leukemia 1/2 mediate the effects of loss of the tumor suppressor deleted in liver cancer 1. in Oncogene 2012
DLC1 (显示 DYNLL1 抗体) is the predominant family member expressed in several normal tissues, and its expression is preferentially reduced in common cancers at these sites.
Fluctuation of reactive oxygen species inhibited migration through reducing the interaction between DLC1 (显示 DYNLL1 抗体) and CAV-1 (显示 CAV1 抗体).
IGF2 may exert its oncofunction, at least partly, through its parasitic miR (显示 MLXIP 抗体)-483 which suppressed DLC-1 (显示 DYNLL1 抗体) in colorectal cancer cells. DLC-1 (显示 DYNLL1 抗体) expression was decreased in colorectal cancer tissues and diminished through transient transfection with miR (显示 MLXIP 抗体)-483-3p.
The results of this study showed for the first time that CpGs of the DLC1 (显示 DYNLL1 抗体)-v1 alternative promoter is frequently hypermethylated in tumors of meningeal origin.
Receptor tyrosine kinase (显示 RET 抗体) activation of RhoA (显示 RHOA 抗体) is mediated by AKT (显示 AKT1 抗体) phosphorylation of DLC1 (显示 DYNLL1 抗体).
Study suggests a mechanism for EZH2 (显示 EZH2 抗体)-H3K27me3 epigenetic repression of DLC1 (显示 DYNLL1 抗体) and multilayered regulation of DLC1 (显示 DYNLL1 抗体)/Rho/ROCK signaling by EZH2 (显示 EZH2 抗体), and advocated the significant pro-metastatic role of EZH2 (显示 EZH2 抗体) via repressing tumor and metastasis suppressors.
The results identify DLC1 (显示 DYNLL1 抗体) as an activator of white and brown adipocyte differentiation, and provide a molecular link between PPARgamma (显示 PPARG 抗体) and Rho pathways.
DLC-1 (显示 DYNLL1 抗体) has a positive regulatory role in endothelial cell angiogenesis.
Subsequent studies have demonstrated that DLC-1 (显示 DYNLL1 抗体) is generally expressed in normal human tissues as well as in rats, while it always exists inactivated or even lost in many human cancers, which characterizes DLC-1 (显示 DYNLL1 抗体) as a potential tumor suppressor. [review]
Tumor suppressor genes deleted in liver cancer 1 (DLC1), F-box/WD-repeat-containing protein 7 (FBXW7 (显示 FBXW7 抗体)), and cadherin-6 (CDH6 (显示 CDH6 抗体)) were identified as presumed targets in Cholangiocarcinoma (CC).Inverse correlation between promoter methylation and expression suggested miR (显示 MLXIP 抗体)-129-2 and members of the miR (显示 MLXIP 抗体)-200 family (miR (显示 MLXIP 抗体)-200a, miR (显示 MLXIP 抗体)-200b, and miR (显示 MLXIP 抗体)-429) as novel tumor suppressors and oncomiRs, respectively, in CC
DLC-1 has a positive regulatory role in endothelial cell angiogenesis.
studies demonstrate that TNS1 (显示 TNS1 抗体) binds to DLC1 and fine-tunes its RhoGAP (显示 ARHGAP1 抗体) activity toward RhoA (显示 RHOA 抗体) and that the TNS1 (显示 TNS1 抗体)-DLC1-RhoA (显示 RHOA 抗体) signaling axis is critical in regulating cellular functions that lead to angiogenesis
Loss of expression of only Dlc1 isoform 2 may be sufficient for the development of thymic tumors and metastasis.
Several genes and biochemical activities collaborate with the inactivation of DLC1 to give rise to cell transformation in MEFs, and the identified genes are relevant to human tumors with low DLC1 expression.
The Dlc1 deficient cells showed altered cytoskeleton structure, increased RhoA (显示 RHOA 抗体) activity and cellular migration.
DLC-1-/- embryos had defects in the neural tube, brain, heart, and placenta
Our data validate DLC1 as a potent tumor suppressor gene and suggest that its loss creates a dependence on the RhoA (显示 RHOA 抗体) pathway that may be targeted therapeutically.
This gene encodes a GTPase-activating protein (GAP) that is a member of the rhoGAP family of proteins which play a role in the regulation of small GTP-binding proteins. GAP family proteins participate in signaling pathways that regulate cell processes involved in cytoskeletal changes. This gene functions as a tumor suppressor gene in a number of common cancers, including prostate, lung, colorectal, and breast cancers. Multiple transcript variants due to alternative promoters and alternative splicing have been found for this gene.
Rho-GTPase-activating protein 7
, START domain-containing protein 12
, StAR-related lipid transfer (START) domain containing 12
, deleted in liver cancer 1 protein
, deleted in liver cancer 1 variant 2
, rho GTPase-activating protein 7
, rho-type GTPase-activating protein 7
, deleted in liver cancer 1
, deleted in liver cancer 1 protein homolog
, stAR-related lipid transfer protein 12
, rho GTPase-activating protein 7-like
, Deleted in liver cancer 1 protein homolog
, Rho-type GTPase-activating protein 7
, rho GTPase activating protein 7